Know Cancer

or
forgot password

A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant


Phase 2
6 Years
N/A
Open (Enrolling)
Both
Transplantation Infection

Thank you

Trial Information

A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant


The Study Drug:

Cidofovir is an anti-viral drug that is designed to treat or prevent infections caused by
certain kinds of viruses.

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the flip of a coin) to 1 of 2 study groups and you will have an equal chance of being
in either group:

- If you are in Group 1, you will receive standard of care drugs and cidofovir. The
doctor will tell you more about the standard of care drugs that you will take and the
risks for them.

- If you are in Group 2, you will only receive standard of care drugs.

Study Drug Administration:

If you are in Group 1, you will receive cidofovir by vein over about 1 hour 3 times per
week. You will also receive standard of care, which may include oral pain drugs taken every
4 to 6 hours as needed, oral drugs for urinary urgency taken 2 times daily, and fluids given
by vein to increase your urination rate.

If you are in Group 2, you will only receive the standard of care, as described above.

Study Visits:

Each week:

- Blood (about 2 tablespoons) will be drawn for routine tests.

- You will have a physical exam, including measurement of your vital signs.

Every 2 weeks, you will complete the questionnaire about urinary problems.

Length of Study:

If you are in Group 1, you may continue taking the study drug for up to 4 weeks. Group 2
will take the standard of care for 4 weeks. If the doctor thinks it is needed Groups 1 and
2 can continue to receive standard of care after this study is over. If your symptoms get
worse during the study and you are not receiving cidofovir, you may be eligible for further
treatments, which may include cidofovir, after the study ends. You will no longer be able to
take the study drug if the disease gets worse or intolerable side effects occur.

Your participation on the study will be over once you have completed the end-of-treatment
visit and the follow-up visit.

End-of-Treatment Visit:

After you finish treatment:

- Urine will be collected to test the level of BK virus.

- You will complete the questionnaire about urinary problems.

Follow-up Visit:

Four (4) weeks after treatment ends:

- You will have a physical exam, including measurement of your vital signs.

- Urine will be collected to test the level of BK virus.

This is an investigational study. Cidofovir is FDA approved and commercially available for
the treatment of several viral infections. Its use in patients with the BK virus after a
stem cell transplant is investigational.

Up to 150 patients will take part in this study. All will be enrolled at MD Anderson.


Inclusion Criteria:



1. HSCT patients with symptomatic hemorrhagic cystitis (minimal Grade 1 symptoms of HC
per NCI criteria) and positive BKV in urine >1x103 DNA copies/ml

2. Age >/= 6 years

3. Patient must sign the informed consent document.

Exclusion Criteria:

1. Creatine clearance < 55 ml/min, calculated using ideal body weight (IBW) using
Cockcroft-Gault equation

2. Concomitant use of foscarnet, liposomal amphotericin B or aminoglycoside

3. Use of cidofovir for bladder instillation

4. Use of formalin or hyperbaric oxygen treatment

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Patients with Microbiologic Response

Outcome Description:

Response defined as improvement in symptoms based on questionnaire, reduction or stability in grade of hemorrhagic cystitis, and level of virus must be a 1 log reduction from baseline when the BKV was first diagnosed.

Outcome Time Frame:

8 weeks

Safety Issue:

Yes

Principal Investigator

Borje S. Andersson, MD,PHD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

2010-0518

NCT ID:

NCT01295645

Start Date:

March 2011

Completion Date:

Related Keywords:

  • Transplantation Infection
  • Stem Cell Transplant
  • Hemorrhagic Cystitis
  • Bladder inflammation
  • Frequent urination
  • Pain
  • Polyomavirus hominis type I
  • BK virus
  • BKV
  • Cidofovir
  • Vistide
  • Cystitis

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030